FASN/SCD-IN-1
FASN/SCD-IN-1 is a Silybin (HY-N0779A) derivative, an orally active inhibitor of Fatty Acid Synthase (FASN)/Stearoyl-CoA Desaturase (SCD). FASN/SCD-IN-1 has shown in vitro activity in inhibiting lipid deposition, reducing FASN and SCD transcriptional levels, and exhibiting antioxidant, anti-inflammatory, and anti-fibrotic activities. FASN/SCD-IN-1 has demonstrated significant hepatoprotective effects in a rat model of acute liver injury. FASN/SCD-IN-1 ameliorates the pathological features of MASH liver, including steatosis, inflammation, and fibrosis in a mouse model of myeloproliferative steatohepatitis (MASH). FASN/SCD-IN-1 can be used to study MASH.
For research use only. We do not sell to patients.
- CAS No.: 3063509-61-2
- Formula: C25H22O9S
- Molecular Weight:498.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
FASN/SCD-IN-1 (Compound A2) (100-200 μM, 20-30 min) shows scavenging ability for DPPH and O2•–, with scavenging rates of 92.9% and 82.9% respectively, with IC50s of 33.4, 28.1 μM, in terms of lipid peroxidation inhibition capacity (LPIC) assay, the inhibition rate of LPIC is 67.0%, with an IC50 of 41.7 μM[1].
FASN/SCD-IN-1 (10-40 μM, 24 h) reduces triglyceride (TG) levels and inhibits lipid accumulation in Palmitic acid (HY-N0830)/Oleic acid (HY-N1446) (PO)-stimulated LO2 cells and primary mouse hepatocytes, decreases fatty acid synthase (FASN) and stearoyl-CoA desaturase (SCD) transcript levels in PO-stimulated LO2 cells, decreases ACACA (encoding acetyl-CoA carboxylase) and FASN in PO-stimulated primary mouse hepatocytes[1].
FASN/SCD-IN-1 (1-10 μM, 24 h) reduces the excessive ROS and IL-6, TNF-α mRNA levels in Carbon tetrachloride CCl4 (HY-Y0298)-stimulated LO2 cells and primary mouse hepatocytes[1].
FASN/SCD-IN-1 (10-40 μM, 48 h) suppresses collagen I and fibronectin (FN) levels in TGF-β-stimulated LX2 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:TGF-β-stimulated LX2 cells
-
Concentration:10 μM, 20 μM, 40 μM
-
Incubation Time:48 h
-
Result:Suppressed collagen I and FN levels.
Parmacokinetics
| Species | Dose | Route | AUC0-∞ | MRT0-∞ | T1/2 | Tmax | Cmax | Vz |
|---|---|---|---|---|---|---|---|---|
| Rat[1] | 150 mg/kg | p.o. | 11599.6 ng·h/mL | 3.51 h | 1.55 h | 1.99 h | 4081.01 ng/mL | 6.91 L |
In Vivo
FASN/SCD-IN-1 (150 mg/kg, p.o., once a day, 4 weeks) reduces steatosis, attenuates oxidative stress, inflammatory response, and liver fibrosis, and therefore markedly ameliorates the progression in HFD + CCl4-induced MASH mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CCl4 (1 mg/kg, i.p.)-induced acute liver injury SD rat (male, 6 weeks) model[1]
-
Dosage:100 mg/kg
-
Administration:i.g. once a day, 7 days
-
Result:Alleviated typical features of fatty liver disease, such as partial yellowing, darkening of the liver margins, white fat granules, and a rough surface.
Reduced the hepatopancreatic somatic index (HSI) and liver-to-body weight ratio.
Reduced serum AST, ALT, and LDH levels.
Reduced liver vacuoles, acute fat deposition, elevation of the MDA level and and restored SOD activity.
-
Animal Model:HFD + CCl4 (0.2 mg/kg, i.p., once a week)-induced MASH C57BL/6 mice (male, 6 weeks) model[1]
-
Dosage:150 mg/kg
-
Administration:p.o., once a day, 4 weeks
-
Result:Protected body weight and counteracts CCl4 toxicity.
Reduced hepatopancreatic somatic index (HSI) and alleviates liver swelling.
Alleviated liver damage and reverses CCl4-induced liver enlargement, pale color, and mottled texture.
Reduced serum AST and ALT levels.
Improved liver structural distortion and reverses CCl4-induced hepatocellular ballooning, inflammation, and steatosis.
Ameliorated the dyslipidemia, reduced the elevated serum TG, cholesterol (CHO), and low-density lipoprotein cholesterol (LDL-c) levels and increased the lowered high-density lipoprotein cholesterol (HDL-c) levels.
Reduced the hepatic TG and CHO levels.
Restored the decreased liver GSH level and decrease the elevated MDA level, restore the decreased levels of both SOD and GSH-Px.
Reduced IL-6 and TNF-α levels, reduced collagen deposition, levels of α-SMA and collagen I in the liver tissue.
Chemical Information
-
CAS No. 3063509-61-2
-
Molecular Weight 498.50
-
Formula C25H22O9S
-
SMILES
OC1=C2C([C@@H]([C@H](OC2=CC(O)=C1)C3=CC4=C(C=C3)OC(CS)C(C5=CC=C(C(OC)=C5)O)O4)O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
How to Select a Suitable Non-Mouse Animal Model
Selecting a suitable non-mouse animal model is a structured decision based on the research question, required anatomy or physiology, disease mechanism, endpoint feasibility, translational relevance, and ethical justification. Non-mouse models are preferred when mice cannot reproduce key human-relevant features, such as organ size, surgical anatomy, cardiovascular physiology, neuroanatomy, immune features, pharmacology, toxicology, or long-term clinical procedures. Candidate species may include rats, rabbits, guinea pigs, ferrets, zebrafish, pigs, sheep, goats, dogs, cats, horses, and non-human primates, but each species must be justified by its specific scientific advantage rather than convenience or tradition. Unresolved questions include how to quantify translational superiority across species, how to balance increased biological relevance against higher ethical burden, and when human-derived systems or new approach methodologies should replace animal use.
-
Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
Masson’s Trichrome (collagen/trichrome staining) is a histological technique that differentially stains tissue compartments using sequential acidic dyes to distinguish collagen from muscle and cytoplasmic components based on dye affinity and tissue permeability differences, enabling visualization of fibrosis and connective tissue architecture in histological sections. The classical formulation typically uses Weigert's iron hematoxylin for nuclear staining, Biebrich scarlet-acid fuchsin for cytoplasm and muscle, and aniline blue (or light green variants) for collagen, producing a characteristic blue/green collagen signal contrasted against red cytoplasm and dark nuclei. The staining principle relies on selective displacement of smaller dye molecules by larger anionic dyes in collagen-rich regions under controlled acidified conditions, which enhances collagen-specific dye retention. This property makes the method widely used for fibrosis assessment in organs such as heart, liver, lung, a
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
-
Liver Histomorphometry
Liver histomorphometry is a quantitative histological approach used to measure structural alterations in hepatic tissue, including parenchymal loss, steatosis, fibrosis, and vascular remodeling, by combining stained tissue section analysis with stereological or computerized image-based measurements. Classical morphometric frameworks quantify volume fractions of liver compartments and fibrotic regions using systematic sampling and image analysis, enabling objective comparison of pathological changes across experimental groups. These approaches are widely applied in liver cirrhosis and fibrosis studies to reduce subjectivity in histological scoring and improve reproducibility of tissue evaluation. Recent methodological advances integrate automated image analysis and radiomics-based extraction of histological features from standard liver stains (e. g. , H&E and fibrotic stains), enabling quantitative correlation between morphometric features and fibrosis stages in non-alcoholic fatty live
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)